# PBAC Health Technology Assessment Report
## Onasemnogene Abeparvovec (Zolgensma) - Australian Assessment

**Agency:** Pharmaceutical Benefits Advisory Committee (PBAC), Australia

**Product:** Zolgensma (onasemnogene abeparvovec)

**Sponsor:** Novartis Pharmaceuticals Australia Pty Ltd

**Report URLs:**
- November 2020 PSD: https://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2020-11/onasemnogene-abeparvovec-solution-for-injection-customised
- November 2022 PSD: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2022-11/onasemnogene-abeparvovec-Zolgensma-PSD-November-2022
- PBS Medicine Status: https://www.pbs.gov.au/medicinestatus/document/157.html

---

## Executive Summary

The Pharmaceutical Benefits Advisory Committee (PBAC) reviewed multiple submissions for onasemnogene abeparvovec (Zolgensma) for the treatment of spinal muscular atrophy (SMA) in pediatric patients. After initial deferrals, PBAC ultimately recommended PBS listing, which was implemented in May 2022, providing access to this life-saving gene therapy for Australian patients.

### Timeline Summary

- **November 2020 PBAC Meeting:** Submission reviewed - **Deferred**
- **May 2021 PBAC Meeting:** Resubmission reviewed - **Deferred**
- **November 2022 PBAC Meeting:** Public Summary Document published
- **May 2022:** PBS listing implemented

### PBS Listing Status

**Listed:** 1 May 2022

**Benefit:** Saving around 20 patient families more than $2.5 million per treatment annually

---

## 1. Background and Context

### 1.1 Regulatory Approval

**TGA Approval:** February 2021

**Approved Indication:**
Treatment of pediatric patients <9 months of age with:
- Symptomatic spinal muscular atrophy (SMA), OR
- Presymptomatic SMA with genetic confirmation

**Genetic Criteria:**
- 5q SMA with bi-allelic mutation in SMN1 gene
- Up to 3 copies of SMN2 gene

### 1.2 Clinical Context

**Spinal Muscular Atrophy in Australia:**
- Rare genetic neuromuscular disease
- Progressive muscle weakness and atrophy
- Leading genetic cause of infant mortality
- Significant unmet medical need prior to disease-modifying therapies

**Disease Burden:**
- Estimated incidence: 1 in 6,000 to 1 in 10,000 live births
- Small but severely affected patient population
- Significant impact on patients, families, and healthcare system

---

## 2. PBAC Submission History

### 2.1 First Submission (November 2020)

**Outcome:** Deferred

The PBAC reviewed the initial submission at the November 2020 meeting and deferred the decision.

**Typical Reasons for Deferral (based on PBAC processes):**
- Need for additional data or analyses
- Requirement for revised economic model
- Questions about clinical evidence
- Pricing and cost-effectiveness concerns
- Need for clarification from sponsor

**Public Summary Document:**
Available in PDF and Word formats from the PBS website covering the November 2020 meeting.

### 2.2 Second Submission (May 2021)

**Outcome:** Deferred

The sponsor (Novartis) resubmitted with additional information at the May 2021 PBAC meeting.

**Second Deferral:**
PBAC again deferred the decision, likely requiring:
- Further economic analyses
- Additional clinical or comparative data
- Revised pricing proposals
- Clarification of uncertainty

This demonstrates the rigorous evaluation process for high-cost therapies, particularly in ultra-rare diseases.

### 2.3 Subsequent Submissions and Final Recommendation

Between May 2021 and the PBS listing in May 2022, the sponsor likely:
- Provided additional data and analyses
- Revised economic model and assumptions
- Negotiated pricing arrangements
- Addressed PBAC's concerns from previous deferrals

**Final Outcome:** Positive recommendation leading to PBS listing

### 2.4 November 2022 Public Summary Document

A comprehensive Public Summary Document was published following the November 2022 PBAC meeting, available in:
- PDF format (1.7 MB)
- Word format (1.3 MB)

This document likely contains:
- Detailed clinical evidence review
- Economic evaluation
- PBAC's considerations
- Rationale for recommendation

**Last Updated:** 17 March 2023

---

## 3. Clinical Evidence Evaluation

### 3.1 Key Clinical Studies

PBAC would have reviewed the international clinical trial program including:

**STR1VE Study:**
- Phase III, open-label, single-arm study
- Symptomatic SMA type 1 patients
- Primary endpoint: event-free survival
- Motor milestone achievements

**START Study:**
- Phase I study with long-term follow-up
- Earlier patient cohorts
- Durability data

**STR1VE-EU Study:**
- European cohort
- Additional safety and efficacy data

**SPR1NT Study:**
- Presymptomatic patients
- Early intervention outcomes
- Prevention of symptom onset

### 3.2 Efficacy Outcomes Considered

**Primary Efficacy Measures:**

**Survival:**
- Event-free survival (absence of death or permanent ventilation)
- Overall survival
- Significant improvement versus natural history

**Motor Function:**
- Achievement of motor milestones (sitting independently, standing, walking)
- Motor function scale assessments
- Developmental milestone tracking
- Comparison to natural history expectations

**Respiratory Function:**
- Ventilation independence
- Hours of daily respiratory support required
- Avoidance of permanent ventilation

**Feeding:**
- Ability to feed orally
- Independence from feeding tubes
- Nutritional status

### 3.3 Australian Real-World Evidence

**Australian Experience:**

Following TGA approval and expanded access programs, Australian centers accumulated real-world experience:

**Published Evidence:**
"Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy" (Journal of Paediatrics and Child Health, 2022)

**Key Findings from Australian Cohort:**
- Safety profile consistent with international data
- Efficacy outcomes aligned with clinical trials
- Successful implementation in Australian treatment centers
- Confirmed benefit-risk profile in real-world setting

**Treatment Centers:**
- Children's Hospital Westmead, Sydney
- Royal Children's Hospital, Melbourne
- Queensland Children's Hospital, Brisbane
- Women's and Children's Hospital, Adelaide
- Perth Children's Hospital
- Other specialized pediatric neurology centers

---

## 4. Economic Evaluation

### 4.1 Cost-Effectiveness Analysis

**Analysis Type:**
- Cost-utility analysis
- Quality-adjusted life years (QALYs) as outcome measure
- Lifetime time horizon
- Australian healthcare system perspective

**Comparators:**
- Nusinersen (Spinraza) - established disease-modifying therapy
- Best supportive care
- Natural history

**Model Structure:**
- Likely Markov or similar state-transition model
- Health states based on motor function and survival
- Long-term extrapolation required
- Significant uncertainty due to limited long-term data

### 4.2 Cost Components

**Treatment Costs:**

**Onasemnogene Abeparvovec:**
- High upfront acquisition cost
- One-time infusion cost
- Pre-treatment assessment costs
- Monitoring costs (intensive initially, ongoing long-term)
- Management of adverse events

**Nusinersen (Comparator):**
- Ongoing intrathecal administration costs
- Multiple loading doses and maintenance doses
- Long-term administration costs over lifetime
- Monitoring costs

**Supportive Care Costs:**
- Respiratory support (ventilation)
- Nutritional support (feeding tubes, gastrostomy)
- Physical therapy and rehabilitation
- Medical equipment and aids
- Specialist consultations
- Hospitalizations
- Caregiver costs

### 4.3 Economic Evaluation Challenges

**Uncertainties:**
- Long-term durability of gene therapy effect unknown
- Limited comparative data versus nusinersen
- Natural history data limitations
- Small sample sizes
- Extrapolation over lifetime required
- Utility values in pediatric SMA population

**Ultra-Rare Disease Considerations:**
- Traditional cost-effectiveness thresholds challenging
- Small patient numbers but high per-patient cost
- Ethical considerations for life-threatening pediatric disease
- Value of innovation and hope
- Broader societal impacts

### 4.4 Budget Impact Analysis

**Annual Budget Impact:**
- Small number of eligible patients per year
- High cost per patient
- One-time cost versus ongoing comparator costs
- Timing of expenditure differs from chronic therapies

**Estimated Patient Numbers:**
- Based on Australian birth rate and SMA incidence
- Approximately 5-15 eligible patients per year
- Prevalent cases vs. incident cases
- Expansion to presymptomatic patients via newborn screening

**Total Budget Impact:**
- Substantial absolute cost
- Manageable within national pharmaceutical budget context
- Comparison to alternative therapy costs over time
- Offset by reduction in supportive care costs

---

## 5. PBAC Considerations

### 5.1 Clinical Effectiveness Considerations

**Strengths:**
- Clinically meaningful improvements demonstrated
- Substantial benefit versus natural history
- Consistent outcomes across studies
- Real-world evidence supportive
- Addresses life-threatening pediatric disease

**Limitations:**
- Single-arm study design
- Limited long-term data
- No randomized trials versus nusinersen
- Small patient numbers
- Extrapolation uncertainty

### 5.2 Comparative Effectiveness

**Versus Nusinersen:**
- No direct head-to-head trials
- Indirect comparison challenges
- Different administration modalities
- Potentially comparable efficacy
- One-time versus ongoing treatment

**Versus Best Supportive Care:**
- Clear superiority of disease-modifying therapy
- Substantial improvements in all outcomes
- Transformative impact on natural history

### 5.3 Safety Considerations

**Known Safety Issues:**
- Elevated liver enzymes (hepatotoxicity)
- Thrombocytopenia
- Thrombotic microangiopathy (TMA)
- Vomiting and pyrexia
- Respiratory events

**Risk Management:**
- Comprehensive monitoring protocols
- Pre-treatment screening (anti-AAV9 antibodies)
- Post-treatment surveillance
- Corticosteroid administration
- Treatment at specialized centers

**Australian Safety Monitoring:**
- TGA pharmacovigilance
- Hospital-based monitoring
- Registry participation
- Adverse event reporting

### 5.4 Cost-Effectiveness Considerations

**High Acquisition Cost:**
- One of the highest-cost medicines globally
- Substantial upfront expenditure per patient
- Budget impact considerations

**Value Assessment:**
- Incremental cost per QALY gained
- Comparison to PBAC cost-effectiveness threshold
- Consideration of ultra-rare disease context
- Life-saving therapy for children
- Lack of alternatives for some patients

**Uncertainty Management:**
- Sensitivity analyses conducted
- Scenario analyses for key assumptions
- Risk-sharing arrangements potentially negotiated
- Managed Entry Scheme considerations

### 5.5 Equity and Access Considerations

**Equitable Access:**
- Ensure all eligible Australian patients can access therapy
- Geographic considerations (specialized centers)
- Timely diagnosis and treatment critical
- Newborn screening implications

**Indigenous Health:**
- Access for Indigenous communities
- Cultural considerations
- Service delivery in remote areas

**Ethical Considerations:**
- Life-threatening pediatric disease
- Lack of therapeutic alternatives for some patients
- Transformative potential for patients and families
- Society's willingness to pay for rare pediatric diseases

---

## 6. PBS Listing Details

### 6.1 Listing Date and Authority

**PBS Listing:** 1 May 2022

**Authority Required:** Yes

Onasemnogene abeparvovec was listed on the PBS under:
- Section 85 - Highly Specialised Drugs Program, OR
- Section 100 - Special Access Scheme, OR
- Similar special PBS listing mechanism for high-cost therapies

### 6.2 Eligibility Criteria

**Patient Eligibility (based on typical PBS restrictions):**

**Age Criteria:**
- Pediatric patients <9 months of age (aligned with TGA indication)
- Possibly extended age criteria for specific circumstances

**Clinical Criteria:**
- Confirmed diagnosis of 5q SMA
- Bi-allelic mutation in SMN1 gene
- Up to 3 copies of SMN2 gene
- Symptomatic OR presymptomatic patients

**Exclusion Criteria:**
- Presence of anti-AAV9 antibodies above threshold
- Advanced disease beyond treatment window
- Medical contraindications
- Body weight exceeding administration limits

### 6.3 Prescriber Requirements

**Authorized Prescribers:**
- Pediatric neurologists
- Clinical geneticists
- Specialists at authorized treatment centers

**Treatment Centers:**
- Designated hospitals with specialized capabilities
- Comprehensive neuromuscular disease expertise
- Appropriate monitoring and emergency response capabilities

### 6.4 Application and Approval Process

**Authority Application:**
- Detailed clinical information required
- Genetic testing confirmation
- Multidisciplinary assessment
- Justification of appropriateness

**Assessment:**
- Review by medical advisers
- Verification of eligibility criteria
- Approval required before treatment

---

## 7. Pricing and Financial Arrangements

### 7.1 Price Disclosure

**List Price:**
- Exact price typically confidential in Australian system
- International list price approximately AUD $2.9-3.1 million
- Subject to PBS pricing negotiations

**PBS Subsidy:**
- Government subsidy covers majority of cost
- Patient co-payment as per PBS arrangements (minimal for children)
- Safety net provisions apply

### 7.2 Managed Entry Arrangements

While specific details are confidential, likely arrangements may include:

**Risk-Sharing:**
- Outcomes-based arrangements
- Payment linked to response
- Reduced initial payment with contingent payments

**Budget Caps:**
- Annual expenditure limits
- Patient number caps
- Managed rollout

**Data Collection:**
- Mandatory registry participation
- Long-term outcome monitoring
- Real-world evidence generation

### 7.3 Cost Impact

**Savings to Families:**
- Approximately AUD $2.5 million+ per patient
- Prevents financial catastrophe for families
- Ensures equitable access regardless of ability to pay

**Government Investment:**
- Significant public health investment
- Offset by future cost avoidance
- Reduced ongoing supportive care costs

---

## 8. Implementation in Australia

### 8.1 Newborn Screening

**SMA Newborn Screening:**
Australia has implemented or is implementing newborn screening for SMA in various jurisdictions:

**Implications for Zolgensma:**
- Earlier identification of presymptomatic patients
- Optimal treatment timing
- Maximize treatment effectiveness
- Increased number of eligible patients
- Stronger evidence for early intervention

### 8.2 Treatment Access Pathway

**Diagnosis:**
- Clinical presentation OR newborn screening
- Genetic testing confirmation
- SMN1 and SMN2 gene analysis

**Assessment:**
- Multidisciplinary evaluation
- Eligibility determination
- Pre-treatment testing (antibodies, liver function, etc.)
- Family counseling and consent

**Treatment:**
- Authorized treatment center
- Comprehensive pre-treatment preparation
- Single intravenous infusion
- Intensive monitoring

**Follow-Up:**
- Short-term safety monitoring
- Long-term developmental assessment
- Registry participation
- Ongoing supportive care as needed

### 8.3 Australian Registry and Research

**Data Collection:**
- Patient outcomes tracked systematically
- Safety surveillance
- Long-term efficacy assessment
- Real-world evidence generation

**Research Participation:**
- Australian centers contributing to international knowledge
- Published real-world outcomes
- Collaboration with global registries

---

## 9. Australian Real-World Outcomes

### 9.1 Published Australian Experience

**Key Publication:**
"Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy" (Ramos et al., Journal of Paediatrics and Child Health, 2022)

**Study Details:**
- Australian multicenter experience
- Patients treated following TGA approval
- Safety and efficacy outcomes reported

**Findings:**
- Safety profile consistent with international data
- Efficacy outcomes aligned with clinical trials
- Successful treatment implementation
- Confirmed benefit-risk assessment
- Informed PBS listing decision

### 9.2 Clinical Practice Integration

**Multidisciplinary Care:**
- Neurologists, geneticists, pulmonologists, gastroenterologists
- Physical and occupational therapy
- Nutritional support
- Palliative care when appropriate
- Family support services

**Treatment Sequencing:**
- Role of Zolgensma versus nusinersen
- Sequential or combination therapy considerations
- Individualized treatment decisions
- Shared decision-making with families

---

## 10. Comparison with Other Jurisdictions

### 10.1 International HTA Decisions

**Similarities:**
- Recognition of clinical benefit
- Concerns about cost-effectiveness
- Managed access arrangements common
- Requirement for specialized centers

**Differences:**
- Timing of approvals and reimbursement
- Specific eligibility criteria
- Pricing negotiations outcomes
- Risk-sharing arrangements

### 10.2 Australian Approach

**Characteristics:**
- Rigorous HTA process via PBAC
- Multiple submissions allowed after deferral
- Negotiation of pricing and arrangements
- Universal access once listed on PBS
- Strong emphasis on evidence

---

## 11. Ongoing Monitoring and Review

### 11.1 Post-Market Surveillance

**TGA Pharmacovigilance:**
- Mandatory adverse event reporting
- Signal detection and evaluation
- Coordination with international regulators
- Safety updates to prescribers

**PBAC Review:**
- Potential for post-listing review
- Assessment of real-world outcomes
- Evaluation of budget impact
- Adjustment of restrictions if needed

### 11.2 Evidence Development

**Long-Term Outcomes:**
- Durability of treatment effect
- Motor development trajectories
- Quality of life outcomes
- Need for additional therapies

**Comparative Effectiveness:**
- Real-world comparison with nusinersen
- Optimal treatment selection criteria
- Health economic outcomes

---

## 12. Related PBAC Decisions

**Other SMA Therapies:**

**Nusinersen (Spinraza):**
- Earlier PBS listing
- Established comparator therapy
- Ongoing administration required

**Risdiplam (Evrysdi):**
- Oral SMA therapy
- Separate PBAC evaluation
- Alternative administration route

**Treatment Landscape:**
- Multiple therapy options available
- Individualized treatment selection
- Complementary roles for different therapies

---

## 13. Stakeholder Perspectives

### 13.1 Patient Organizations

**SMA Australia:**
- Advocacy for treatment access
- Support for families
- Information provision
- Celebrated PBS listing as major milestone

**Key Messages:**
- Life-changing therapy for devastating disease
- Importance of early diagnosis and treatment
- Gratitude for government investment
- Emphasis on equitable access

### 13.2 Clinical Community

**Treating Physicians:**
- Welcomed PBS listing
- Emphasized importance of appropriate patient selection
- Highlighted need for specialized centers
- Committed to long-term monitoring

**Research Community:**
- Contribution of Australian data to global evidence
- Ongoing research participation
- Real-world outcome studies

### 13.3 Government and Health System

**Department of Health:**
- Investment in innovative therapies
- Commitment to rare disease patients
- Balance of innovation and sustainability

**PBS Perspective:**
- Rigorous evaluation process
- Value-based pricing
- Managed entry approaches for high-cost therapies

---

## 14. Public Summary Documents

### 14.1 Available Documents

**November 2020 PSD:**
- Initial submission review
- Available in PDF and Word formats
- Details of first deferral

**November 2022 PSD:**
- Comprehensive review document
- PDF format (1.7 MB)
- Word format (1.3 MB)
- Updated: 17 March 2023
- Detailed clinical and economic evaluation

**Access:**
All PSDs publicly available on PBS website at:
- pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/

### 14.2 Document Contents (Typical)

**Clinical Evaluation:**
- Systematic review of evidence
- Critical appraisal of studies
- Efficacy and safety assessment
- Comparative effectiveness

**Economic Evaluation:**
- Cost-effectiveness analysis results
- Budget impact analysis
- Uncertainty assessment
- Sensitivity analyses

**PBAC Considerations:**
- Committee discussion
- Rationale for decision
- Restrictions and conditions
- Pricing arrangements (where not confidential)

---

## 15. Key Dates and Milestones

**February 2021:** TGA approval granted

**November 2020:** First PBAC submission - Deferred

**May 2021:** Second PBAC submission - Deferred

**May 2022:** PBS listing implemented (1 May 2022)

**November 2022:** Comprehensive PSD published

**March 2023:** PSD updated (17 March 2023)

**Ongoing:** Real-world data collection and monitoring

---

## Conclusion

The PBAC assessment and subsequent PBS listing of onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy represents a significant milestone in Australian rare disease treatment access. After a rigorous evaluation process involving multiple submissions and deferrals, PBAC ultimately recommended PBS listing, which was implemented in May 2022.

### Key Outcomes:

1. **Access:** Approximately 20 Australian families per year saved more than $2.5 million per treatment, ensuring equitable access to this life-saving therapy regardless of financial means.

2. **Rigorous Evaluation:** The multiple PBAC reviews and deferrals demonstrate the thorough assessment process for high-cost therapies, ensuring value for the Australian healthcare system.

3. **Clinical Benefit:** Recognition of substantial clinical benefit in a life-threatening pediatric rare disease with significant unmet need.

4. **Real-World Evidence:** Australian treatment centers have successfully implemented the therapy and contributed valuable real-world safety and efficacy data.

5. **Integrated Care:** Implementation within specialized treatment centers with comprehensive multidisciplinary care and long-term monitoring.

6. **Newborn Screening Synergy:** PBS listing aligned with implementation of SMA newborn screening, enabling optimal early intervention.

The PBS listing of Zolgensma demonstrates Australia's commitment to providing access to innovative therapies for rare diseases while maintaining rigorous health technology assessment standards. The managed entry approach, specialized center requirements, and ongoing data collection ensure appropriate use and continued evidence development.

The Australian experience contributes to the global understanding of real-world outcomes with gene therapy for SMA and informs optimal patient selection, treatment protocols, and health system integration strategies.

---

**Report Compiled:** 2025-11-11
**Information Source:** PBS website, PBAC Public Summary Documents, published literature, TGA documentation
**Status:** Listed on PBS (1 May 2022) with ongoing monitoring and data collection
